Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2011. The report details a specific corporate action regarding share repurchases executed on July 25, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share buyback activity and capital structure updates.
- Shares Purchased: 1,600,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,370.0 pence per share; lowest price paid was 1,338.0 pence per share.
- Treasury Holdings (Settled): 489,154,284 shares (8.73% of total issued share capital).
- Treasury Holdings (Including Unsettled): 493,104,284 shares (9.64% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,114,452,892 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,600,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.64% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves strictly as a notification of the share repurchase transaction and the resulting capital structure.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (489,154,284 settled) against the company's latest capitalization table.
- Confirm the total issued share capital excluding Treasury shares (5,114,452,892) for voting rights calculations.
- Check the average price paid per share against the reported range (1,338.0 to 1,370.0 pence) to assess execution efficiency.
- Review the impact of the 9.64% Treasury holding on total voting rights distribution.